Research Paper Volume 13, Issue 17 pp 21102—21121

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

Low-dose BTZ enhances the cell apoptotic effect induced by low-dose BGB-3111 in the MCL cells. (A) Cell apoptotic distribution of the Jeko-1, Rec-1, and Z138 cells after being treated with low-dose BGB-3111, low-dose BTZ, and their combination for 48 h. (B) The cell apoptotic rate was detected by flow cytometry. **p

Figure 7. Low-dose BTZ enhances the cell apoptotic effect induced by low-dose BGB-3111 in the MCL cells. (A) Cell apoptotic distribution of the Jeko-1, Rec-1, and Z138 cells after being treated with low-dose BGB-3111, low-dose BTZ, and their combination for 48 h. (B) The cell apoptotic rate was detected by flow cytometry. **p < 0.01. The expression levels of the apoptosis-related proteins in Jeko-1, Rec-1, and Z138 cells after treating with low-dose BGB-3111, low-dose BTZ, and their combination for 48 h.